22 results on '"Zoi, Katerina"'
Search Results
2. A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity.
3. Real life treatment experience and outcome of consecutively hospitalised patients with SARS-CoV-2 pneumonia by Omicron-1 vs Delta variants.
4. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
5. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
6. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms
7. The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis
8. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
9. Is JAK2 V617F mutation more than a diagnostic index?: A meta-analysis of clinical outcomes in essential thrombocythemia
10. The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis
11. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
12. Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity
13. Genomics of Myeloproliferative Neoplasms.
14. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
15. Routine application of a novel MLPA-based first-line screening test uncovers clinically relevant copy number aberrations in haematological malignancies undetectable by conventional cytogenetics.
16. The ERCC2 Gln/ Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis.
17. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
18. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
19. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
20. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
21. EZH2 mutational status predicts poor survival in myelofibrosis.
22. Switch in X-inactivation in a JAK2 V617F-negative case of polycythemia vera with two acquired X-autosome translocations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.